MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 1,594 patients (estimated)
- Sponsors
- European Myeloma Network
- Collaborators
- Janssen Pharmaceuticals
- Tags
- Bispecific Antibody, Bispecific T Cell Engager (BiTE), B-Cell Maturation Antigen (BCMA), CD3, Maintenance, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2053
- NCT Identifier
- NCT05243797
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.